The story of Rejuvenation Technologies begins with a profound scientific breakthrough and a sudden shift in academic focus. In 1998, human telomeres—the protective caps at the ends of DNA strands that dictate cellular aging—were artificially extended for the very first time. John Ramunas was a fourth-year Electrical Engineering student when he read about this incredible feat. Recognizing the massive implications for human longevity and disease prevention, he immediately switched his major to Biochemistry.

 

Driven by the desire to translate telomere science into tangible healthspan extension, Ramunas found his way to Stanford University. There, he joined the laboratory of renowned researcher Dr. Helen Blau, whose cutting-edge work on the role of short telomeres in Duchenne muscular dystrophy aligned perfectly with his own ambitions. It was in this dynamic academic environment that Ramunas met his future co-founder, Dr. Glenn Markov. Working alongside Dr. Blau, Ramunas and Markov focused on the therapeutic potential of telomere extension. They knew that people with naturally longer telomeres generally live longer, healthier lives, but safely delivering the enzyme responsible for this—telomerase reverse transcriptase (TERT)—remained a massive hurdle.

 

Through years of rigorous research, the team conceptualized a novel approach: utilizing messenger RNA (mRNA) to deliver telomerase. Unlike traditional gene therapies that permanently alter a cell's DNA and carry risks of cellular immortalization, their synthetic mRNA approach was designed to be transient. It would deliver a brief, safe burst of telomerase to the cell, extending the telomere, and then naturally degrade. The breakthrough was published in the FASEB Journal, demonstrating that a single dose could effectively rewind the cellular clock, reversing years of telomere attrition in a matter of days.

 

Realizing the massive clinical potential of their discovery, Ramunas and Markov spun their research out of Stanford and officially launched Rejuvenation Technologies in 2018. The company quickly gained traction, entering the prestigious Y Combinator accelerator program and capturing the attention of the wider biotech community.

 

To turn their mRNA technology into a viable therapeutic, the founders knew they needed an efficient delivery vehicle. Rejuvenation Technologies went on to develop custom, tissue-targeted lipid nanoparticles (LNPs) capable of safely ferrying the TERT mRNA directly to vital organs like the liver, lungs, bone marrow, and peripheral circulation. Pre-clinical models yielded remarkable results, showing unprecedented efficacy in reversing models of oncology, infectious disease, bone marrow failure, cytopenia, emphysema, liver cirrhosis, and pulmonary fibrosis.

 

Today, backed by over $15 million in funding from major investors like Khosla Ventures and grants, Rejuvenation Technologies is headquartered in the heart of Silicon Valley. While their ultimate mission remains extending the overall human healthspan, the company is pragmatically focusing its current clinical pipeline on treating fatal diseases with relatively tractable clinical trial designs including oncology and bone marrow failure. By saving the lives of patients with critical unmet medical needs today, Rejuvenation Technologies is laying the essential groundwork to treat the broader mechanisms of aging tomorrow.